Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News
Healthcare Shares
Fundie names underappreciated ASX biotech share with ‘significant upside’
Share Gainers
The Neuren Pharmaceuticals (ASX:NEU) share price has soared 102% so far this month. Here’s why
Share Gainers
3 ASX shares giving the gift of gains heading into Christmas
Healthcare Shares
Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results
Share Gainers
Here’s why the Neuren Pharmaceuticals (ASX:NEU) share price is up 11%
Share Market News
Why the Neuren (ASX:NEU) share price is moving higher today
Share Market News
The Neuren (ASX:NEU) share price is falling today despite positive news
Share Fallers
Why this small cap ASX healthcare share is dropping lower today
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.
NEU Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
16 May 2022 | $3.68 | $0.03 | 0.82% | 179,850 | $3.61 | $3.82 | $3.58 |
13 May 2022 | $3.65 | $0.10 | 2.82% | 206,458 | $3.57 | $3.67 | $3.47 |
12 May 2022 | $3.55 | $-0.19 | -5.08% | 196,941 | $3.71 | $3.73 | $3.53 |
11 May 2022 | $3.74 | $0.04 | 1.08% | 88,989 | $3.70 | $3.78 | $3.67 |
10 May 2022 | $3.70 | $0.09 | 2.49% | 154,533 | $3.52 | $3.71 | $3.46 |
09 May 2022 | $3.61 | $-0.14 | -3.73% | 177,945 | $3.70 | $3.73 | $3.56 |
06 May 2022 | $3.75 | $-0.05 | -1.32% | 77,265 | $3.76 | $3.76 | $3.66 |
05 May 2022 | $3.80 | $0.10 | 2.70% | 124,719 | $3.70 | $3.80 | $3.69 |
04 May 2022 | $3.70 | $-0.10 | -2.63% | 51,528 | $3.80 | $3.82 | $3.70 |
03 May 2022 | $3.80 | $0.05 | 1.33% | 151,887 | $3.72 | $3.84 | $3.72 |
02 May 2022 | $3.75 | $-0.08 | -2.09% | 160,396 | $3.80 | $3.85 | $3.66 |
29 Apr 2022 | $3.83 | $0.03 | 0.79% | 82,143 | $3.81 | $3.83 | $3.75 |
28 Apr 2022 | $3.80 | $-0.06 | -1.55% | 109,913 | $3.80 | $3.86 | $3.77 |
27 Apr 2022 | $3.86 | $0.01 | 0.26% | 229,547 | $3.80 | $3.88 | $3.77 |
26 Apr 2022 | $3.85 | $-0.09 | -2.28% | 67,254 | $3.82 | $3.92 | $3.80 |
22 Apr 2022 | $3.94 | $0.01 | 0.25% | 101,970 | $3.95 | $3.97 | $3.88 |
21 Apr 2022 | $3.93 | $0.03 | 0.77% | 77,008 | $3.95 | $3.99 | $3.86 |
20 Apr 2022 | $3.90 | $0.02 | 0.52% | 95,041 | $3.85 | $3.91 | $3.83 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
18 Oct 2021 | Dianne Angus | Buy | 30 | $59,316 | On-market trade. |
08 Oct 2021 | Jonathan (Jon) Pilcher | Buy | 7 | $15,000 | Participation in share purchase plan. |
08 Oct 2021 | Jenny Harry | Buy | 9 | $20,000 | Participation in share purchase plan. |
08 Oct 2021 | Patrick Davies | Buy | 14 | $30,000 | Participation in share purchase plan. |
24 Jun 2021 | Patrick Davies | Buy | 43 | $61,172 | On-market trade. |
15 Jun 2021 | Jonathan (Jon) Pilcher | Buy | 19 | $25,000 | On-market trade. |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Trevor D Scott | Non-Executive Director | Mar 2002 | Dr Scott is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a range of industries. Trevor serves on corporate boards and is also serving as chairman at some corporates. |
Ms Dianne Margaret Angus | Non-Executive Director | Jul 2018 | Ms Angus has worked as a senior executive and non-executive director within the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created range of global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory & Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. She has forged partnerships with key medical opinion leaders to create clinical research programs and driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over fifteen years experience in listed company, she has expertise in business development, capital raising, investor relations, regulatory affairs and intellectual property, together with corporate governance and compliance capabilities. |
Mr Jonathan (Jon) Charles Pilcher | Chief Executive OfficerManaging Director | Aug 2013 | Mr Pilcher has financial and capital markets knowledge with a science background, Jon has corporate and R&D executive experience in international listed pharmaceutical companies. |
Dr Jenny Lee Harry | Non-Executive Director | Jul 2018 | Dr Harry has 20 years experience in executive management of companies in the biotechnology and biopharmaceutical sectors. As CEO and Managing Director of Tyrian Diagnostics, Jenny transformed the company from an R&D business to a diagnostics company and oversaw development of the company's first products through to commercialisation and early revenue generation. She is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. Jenny is currently a Non-Executive Director on the boards of Ondek Pty Ltd. |
Mr Patrick Davies | Non-Executive DirectorNon-Executive Chairman | Jul 2018 | Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. He is a director on other corporate boards and provides advice to a range of healthcare businesses and investors. |
Ms Lauren Frazer | Chief Financial OfficerCompany Secretary | Aug 2020 | - |
Lauren Frazer | Chief Financial OfficerCompany Secretary | - | |
Larry Glass | Chief Science Officer | - | |
James Shaw | Vice President Clinical & Regulatory Operations | - | |
Nancy Jones | Vice President Clinical Development | - | |
Clive Blower | Vice President Product Development | - |
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited Gsco Eca | 14,321,650 | 12.50% |
Cameron Richard Pty Ltd | 5,865,240 | 5.12% |
Citicorp Nominees Pty Limited | 4,811,785 | 4.20% |
Stuart Andrew Pty Ltd | 2,951,929 | 2.58% |
National Nominees Limited | 2,951,041 | 2.57% |
HSBC Custody Nominees (Australia) Limited | 2,948,200 | 2.57% |
Linwierik Super Pty Ltd | 2,642,143 | 2.31% |
Brispot Nominees Pty Ltd | 2,482,733 | 2.17% |
Essex Castle Limited | 2,369,251 | 2.07% |
Smithley Super Pty Ltd | 2,140,000 | 1.87% |
Hobson Wealth Custodians Ltd | 1,580,145 | 1.38% |
MXB Investments LLC | 1,330,000 | 1.16% |
CS Fourth Nominees Pty Limited | 1,234,490 | 1.08% |
UBS Nominees Pty Ltd | 1,207,722 | 1.05% |
First Colbyco Pty Ltd | 1,028,520 | 0.90% |
Dr Trevor Scott | 1,000,000 | 0.87% |
Dr Robin Lance Congreve | 991,637 | 0.87% |
Dr Richard Spencer Treagus | 903,500 | 0.79% |
BNP Paribas Nominees Pty Ltd Six Sis Ltd | 735,859 | 0.64% |
Namarong Investments Pty Ltd | 555,556 | 0.48% |